On Tuesday, Lucid Diagnostics Inc (NASDAQ: LUCD) opened higher 3.33% from the last session, before settling in for the closing price of $1.50. Price fluctuations for LUCD have ranged from $0.63 to $1.63 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 119.69%. Company’s average yearly earnings per share was noted 29.75% at the time writing. With a float of $31.75 million, this company’s outstanding shares have now reached $63.07 million.
Let’s determine the extent of company efficiency that accounts for 72 employees. In terms of profitability, gross margin is -85.49%, operating margin of -1077.37%, and the pretax margin is -1069.9%.
Lucid Diagnostics Inc (LUCD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Lucid Diagnostics Inc is 62.03%, while institutional ownership is 5.40%.
Lucid Diagnostics Inc (LUCD) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.08% during the next five years compared to -54.43% drop over the previous five years of trading.
Lucid Diagnostics Inc (NASDAQ: LUCD) Trading Performance Indicators
Check out the current performance indicators for Lucid Diagnostics Inc (LUCD). In the past quarter, the stock posted a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Lucid Diagnostics Inc (LUCD)
Looking closely at Lucid Diagnostics Inc (NASDAQ: LUCD), its last 5-days average volume was 1.17 million, which is a jump from its year-to-date volume of 0.64 million. As of the previous 9 days, the stock’s Stochastic %D was 80.69%. Additionally, its Average True Range was 0.13.
During the past 100 days, Lucid Diagnostics Inc’s (LUCD) raw stochastic average was set at 90.60%, which indicates a significant increase from 88.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.86% in the past 14 days, which was higher than the 70.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2149, while its 200-day Moving Average is $0.9345. However, in the short run, Lucid Diagnostics Inc’s stock first resistance to watch stands at $1.5867. Second resistance stands at $1.6233. The third major resistance level sits at $1.6767. If the price goes on to break the first support level at $1.4967, it is likely to go to the next support level at $1.4433. Now, if the price goes above the second support level, the third support stands at $1.4067.
Lucid Diagnostics Inc (NASDAQ: LUCD) Key Stats
There are currently 59,342K shares outstanding in the company with a market cap of 134.63 million. Presently, the company’s annual sales total 2,430 K according to its annual income of -52,670 K. Last quarter, the company’s sales amounted to 1,170 K and its income totaled -12,370 K.
